摘要
目的:探讨乐孕宁口服液联合盐酸利托君治疗晚期先兆流产的疗效及对临床症状和血清孕酮(P)、妊娠相关蛋白(PAPP-A)、人绒毛膜促性腺激素(HCG)的影响。方法:研究对象选择我院2020年9月-2021年6月期间收治的80例晚期先兆流产患者,根据信封抽签法将患者分为对照组(给予盐酸利托君治疗)和观察组(给予乐孕宁口服液联合盐酸利托君治疗),各为40例。观察并对比两组患者的疗效、血清指标、临床指标及药物不良反应。结果:观察组的临床总有效率明显较对照组高(P<0.05)。观察组的阴道出血停止时间、住院时间短于对照组,妊娠延长时间长于对照组,保胎成功率高于对照组(P<0.05)。治疗结束后,观察组的血清P、PAPP-A、HCG水平高于对照组(P<0.05)。两组不良反应发生率组间对比无差异(P>0.05)。结论:晚期先兆流产患者采用乐孕宁口服液联合盐酸利托君治疗效果较好,可调高血清P、PAPP-A、HCG水平,改善患者临床症状,且用药安全。
Objective: To investigate the efficacy of leyuining oral liquid combined with ritodrine hydrochloride in the treatment of late threatened miscarriage and its effect on clinical symptoms and serum progesterone(P), pregnancy associated protein(PAPP-A)and human chorionic gonadotropin(HCG). Methods: The subjects were 80 patients with late threatened miscarriage who were treated in our hospital from September 2020 to June 2021 were selected. According to the envelope lottery method, the patients were divided into control group(ritodrine hydrochloride treatment) and observation group(leyunning oral liquid combined with ritodrine hydrochloride treatment), with 40 cases each. The efficacy, serum indexes, clinical indexes and drug adverse reactions were observed and compared between the two groups. Results: The total clinical effective rate of the observation group was higher than that of the control group(P<0.05). The stopping time of vaginal bleeding and hospitalization time of the observation group were shorter than those of the control group,the extension time of pregnancy was longer than that of the control group, and the success rate of fetal protection was higher than that of the control group(P<0.05). After treatment, the levels of serum P, PAPP-A and HCG of the observation group were higher than those of the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion: The treatment of patients with late threatened miscarriage with leyunning oral liquid combined with ritodrine hydrochloride has a good effect, which can increase the levels of serum P, PAPP-A and HCG, improve the clinical symptoms, and the drug is safe.
作者
尚会敏
杨丽娟
刘然
张琳
牛贝贝
SHANG Hui-min;YANG Li-juan;LIU Ran;ZHANG Lin;NIU Bei-bei(Fifth Department of Obstetrics,Shijiazhuang Maternal and Child Health Hospital,Shijiazhuang,Hebei,050000,China;Prenatal Control Center,Shijiazhuang Maternal and Child Health Hospital,Shijiazhuang,Hebei,050000,China)
出处
《现代生物医学进展》
CAS
2023年第3期584-587,共4页
Progress in Modern Biomedicine
基金
河北省中医药管理局科研计划项目(2019472)。
关键词
乐孕宁口服液
盐酸利托君
晚期
先兆流产
临床症状
孕酮
妊娠相关蛋白
人绒毛膜促性腺激素
Leyuining oral liquid
Ritodrine hydrochloride
Late
Threatened miscarriage
Clinical symptoms
Progesterone
Pregnancy associated protein
Human chorionic gonadotropin